Progenity, Inc.

52 articles about Progenity, Inc.

• Progenity Announces Proposed Convertible Senior Notes Offering - Dec 01, 2020

  12/1/2020

  Progenity, Inc. announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of convertible senior notes due 2025 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™ Test

  11/20/2020

  High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia

• Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium

  11/17/2020

  Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, will be presenting at the San Antonio Breast Cancer Virtual Symposium (SABCS) set to take place December 8-11, 2020. The data presented will be a part of the event’s Spotlight Session Poster Presenters. Details of the presentation are as follows: Title - Describing the cancer spectru

• Progenity to Participate in the 32nd Annual Piper Sandler Healthcare Conference

  11/16/2020

  Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020. The pre-recorded fireside chat will be accessible beginning November

• Progenity to Host Preeclampsia Virtual R&D Day on November 20, 2020

  11/13/2020

  Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will host a Preeclampsia Virtual R&D Day on November 20, 2020 from 11 a.m. to 1 p.m. ET (8 a.m. to 10 a.m. PT). Members of Progenity’s senior management team and select guest speakers will provide an in-depth discussion of the company’s ongoing clinical develop

• Progenity Provides Corporate Updates and Reports Third Quarter 2020 Financial Results

  11/9/2020

  Progenity, Inc., a biotechnology company with an established track record of success in developing and commercializing molecular testing products, provided corporate updates and reported financial results for the third quarter ended September 30, 2020.

• Progenity Announces Encouraging Preclinical Data Supporting the Potential of the Company’s Oral Drug Delivery System in Targeting the Colon

  11/6/2020

  Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, is pleased to announce positive preliminary preclinical data regarding the performance of its oral drug delivery system (DDS). The DDS capsule uses a proprietary autonomous localization technology designed to identify the ileal/ileocecal region of the GI tract. Because the DDS localizatio

• Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update

  11/3/2020

  Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a co

• Progenity Announces Successful Achievement of its Preeclampsia Test Analytical Verification Milestone

  10/29/2020

  Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced a key achievement in the verification of its preeclampsia rule-out test, a significant milestone demonstrating the robustness of the underlying assays

• Progenity Presents Data from Award-Winning Abstract on Novel Ingestible Lab-in-a-Capsule at American College of Gastroenterology (ACG) 2020 Virtual Annual Meeting

  10/27/2020

  Oral and poster presentations feature data on the use of PIL Dx to assess and diagnose SIBO

• Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia

  10/1/2020

  Progenity, Inc., a biotechnology company with an established track record of success in developing and commercializing molecular testing products, announced support for the Preeclampsia Foundation’s recent call to action advocating for accelerating the development and clinical adoption of biomarker tests for the diagnosis of preeclampsia, a life-threatening hypertensive disorder of pregnancy.

• Progenity to Participate in Two Upcoming Investor Conferences

  9/2/2020

  Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, is scheduled to participate in two upcoming virtual investor conferences: A presentation at Baird’s 2020 Global Healthcare Conference at 12:15 p.m. ET / 9:15 a.m. PT on September 9, 202